Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

So in the upcoming large scale P2b/3 study,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Doc328 Member Profile
 
Followed By 26
Posts 1,070
Boards Moderated 0
Alias Born 03/04/18
160x600 placeholder
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People wit... GlobeNewswire Inc. - 1/11/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference GlobeNewswire Inc. - 1/6/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:28:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:26:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:25:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:23:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:20:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/28/2020 5:29:22 PM
Annual Report (10-k) Edgar (US Regulatory) - 12/28/2020 5:28:26 PM
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates GlobeNewswire Inc. - 12/28/2020 7:00:00 AM
Biotech Report; Upcoming FDA Reviews and Promising Pipelines InvestorsHub NewsWire - 12/22/2020 8:20:00 AM
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 GlobeNewswire Inc. - 12/22/2020 7:00:00 AM
Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thal... GlobeNewswire Inc. - 12/21/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2020 7:09:21 AM
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. P... GlobeNewswire Inc. - 12/15/2020 7:00:00 AM
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (b... GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire Inc. - 11/25/2020 7:00:00 AM
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Demen... GlobeNewswire Inc. - 11/6/2020 10:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 7:05:29 AM
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-... GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial GlobeNewswire Inc. - 9/10/2020 7:00:10 AM
Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences GlobeNewswire Inc. - 9/8/2020 7:00:10 AM
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for C... GlobeNewswire Inc. - 8/19/2020 7:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 4:11:04 PM
Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Doc328   Saturday, 08/04/18 10:44:10 AM
Re: tradeherpete post# 161445
Post # of 293658 
Quote:
So in the upcoming large scale P2b/3 study, in 450 patients with early AD, we are planning to look at 2 aspects again, stratification regarding the genomics of the patients. We look at Wild types of the S1R gene carriers vs variant receptor carriers. And we expect a differential response depending on the genetic background.




So, it looks like they will be enrolling all genetic types. Thus, about 360 patients will be S1R-WT and about 90 patients will be S1R-var. Then at study end they will analyze the data stratified by the gene.

The proposed P2/3 looks well designed (placebo controlled, randomized, standard outcomes such as ADAS-cog and CDR-SB, etc)and should be large enough to get real data. I look forward to those results. The only thing I don't like about the study is that they have MMSE 20-28 as inclusion criteria (based on HH's slide at AAIC) and many MMSE 27 and 28 (MCI not mild AD) patients would not be expected to decline over 48 weeks. This potentially weakens a treatment effect if the numbers of these patients are too high.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences